Download PDF
Aktuelle Neurologie 2005; 32(10): 584-588
DOI: 10.1055/s-2005-866846
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Therapie des Morbus Parkinson unter Kosten- und Qualitätsaspekten

Therapy of Idiopathic Parkinson's Disease - Aspects of Costs and QualityT.  Müller1 , J.  Fritze1
  • 1Neurologische Universitätsklinik im St.-Josef-Hospital, Ruhr-Universität Bochum
Further Information

Publication History

Publication Date:
05 September 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zunehmend werden die direkten Kosten der Therapie des Morbus Parkinson diskutiert und reglementiert. Ziel dieser Übersicht ist eine Darstellung und Wertung der Ergebnisse gesundheitsökonomischer Studien zur Therapie des Morbus Parkinson. Kurzfristige Kosteneinsparung kann durch Verordnen günstiger Levodopapräparate zwar erreicht werden, langfristig führt dieses Behandlungskonzept aber eher zum Auftreten von Fluktuationen mit deren daraus resultierenden Folgekosten. Langzeitaspekte und Qualität einer notwendigen ganzheitlichen Therapie werden nur teilweise in den vorliegenden Studien berücksichtigt. Letztendlich sollten aber medizinische und nicht finanzielle Argumente entscheidend sein und dem Kranken der therapeutische Fortschritt aus kurzfristigen Kostengründen nicht vorenthalten werden, da sich neben einer verbesserten Lebensqualität so vor allem die sekundären indirekten Folgen dieser Erkrankung auch auf Kostenebene nachhaltig langfristig beeinflussen lassen.

Abstract

There is an increasing debate and control of direct costs of therapy of Parkinson's disease (PD). Aim of this review is to evaluate and discuss results of previously performed pharmacoeconomic trials on the cost effectiveness of therapy of PD patients. Levodopa preparations appear to be cheaper in the short-term, but in the long run this treatment without dopamine agonists causes earlier onset of motor complications with their resulting increase of direct and indirect costs and limited quality of life. However, these long-term aspects and quality of therapy, which also involves social viewpoints, are only partially considered. In the end, medical and not financial aspects are essential. The PD patient should benefit from progress in the treatment of PD. This will improve quality of life and at least decrease in particular secondary indirect costs of PD in the long-term.

Literatur

  • 1 Singer E. Social costs of Parkinson's disease.  J Chronic Dis. 1973;  26 243-254
    CrossrefPubMedGoogle Scholar
  • 2 Clarke C E. Medical management of Parkinson's disease.  J Neurol Neurosurg Psychiatry. 2002;  72, Suppl 1 I22-I27
    CrossrefPubMedGoogle Scholar
  • 3 Dodel R C, Singer M, Kohne-Volland R. et al . The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.  Pharmacoeconomics. 1998;  14 299-312
    CrossrefPubMedGoogle Scholar
  • 4 Dodel R C, Eggert K M, Singer M S. et al . Costs of drug treatment in Parkinson's disease.  Mov Disord. 1998;  13 249-254
    CrossrefPubMedGoogle Scholar
  • 5 Hoerger T J, Bala M V, Rowland C. et al . Cost effectiveness of pramipexole in Parkinson's disease in the US.  Pharmacoeconomics. 1998;  14 541-557
    PubMedGoogle Scholar
  • 6 Stamm T, Spycher S, Engfer A, Fahrenkrug E. Krankheitskosten des Morbus Parkinson in Deutschland.  Psycho. 1996;  22 212-228
    PubMedGoogle Scholar
  • 7 Ogunniyi A. Treatment of parkinsonian syndromes in developing countries.  Afr J Med Sci. 1997;  26 101-103
    PubMedGoogle Scholar
  • 8 Rubenstein L M, DeLeo A, Chrischilles E A. Economic and health-related quality of life considerations of new therapies in Parkinson's disease.  Pharmacoeconomics. 2001;  19 729-752
    PubMedGoogle Scholar
  • 9 Rubenstein L M, Chrischilles E A, Voelker M D. The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey.  Pharmacoeconomics. 1997;  12 486-498
    CrossrefPubMedGoogle Scholar
  • 10 Tomaszewski K J, Holloway R G. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis.  Neurology. 2001;  57 663-671
    PubMedGoogle Scholar
  • 11 Whetten-Goldstein K, Sloan F, Kulas E. et al . The burden of Parkinson's disease on society, family, and the individual.  J Am Geriatr Soc. 1997;  45 844-849
    CrossrefPubMedGoogle Scholar
  • 12 Dodel R C, Singer M, Kohne-Volland R. et al . Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs.  Nervenarzt. 1997;  68 978-984
    CrossrefPubMedGoogle Scholar
  • 13 Keller S, Kessler T, Meuser T. et al . Analysis of direct costs in therapy of Parkinson disease.  Nervenarzt. 2003;  74 1105-1109
    CrossrefPubMedGoogle Scholar
  • 14 Müller T, Voss B, Hellwig K. et al . Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.  CNS Drugs. 2004;  18 105-111
    PubMedGoogle Scholar
  • 15 Müller T, Voss B, Hellwig K, Przuntek H. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.  NeuroRehabilitation. 2003;  18 271-275
    PubMedGoogle Scholar
  • 16 LePen C, Wait S, Moutard-Martin F. et al . Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.  Pharmacoeconomics. 1999;  16 59-69
    CrossrefPubMedGoogle Scholar
  • 17 Muhlack S, Woitalla D, Welnic J. et al . Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.  Neurosci Lett. 2004;  363 284-287
    CrossrefPubMedGoogle Scholar
  • 18 Müller T, Kuhn W, Przuntek H. Therapie mit Amantadinsalzen. In: Oertel WH (Hrsg) Pharmakotherapie der Parkinson-Krankheit. 11. Frankfurter Symposion 12. - 14.3.1998. Stuttgart; Schattauer Basel, Grenzach-Wyhlen; Editiones Roche 2004: 123-130
    Google Scholar
  • 19 Fritze J. Psychopharmacological regulations. Results and commentary to the report on drug regulations 2002.  Nervenarzt. 2003;  74 301-306
    CrossrefPubMedGoogle Scholar
  • 20 Fritze J, Schmauss M. Alteration of the guidelines on pharmaceuticals of the National Committee of Physicians and Health Insurers with regard to atypical neuroleptics. Statement of the German Scoiety of Psychiatry, Psychotherapy and Neurology (DGPPN).  Nervenarzt. 2003;  74 97-99
    PubMedGoogle Scholar
  • 21 Fritze J, Schmauss M. Off-label use in psychopharmacotherapy.  Nervenarzt. 2002;  73 796-799
    CrossrefPubMedGoogle Scholar
  • 22 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders.  Mov Disord. 1997;  12 483-496
    CrossrefPubMedGoogle Scholar
  • 23 Fischer P A, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine.  J Neural Transm Park Dis Dement Sect. 1990;  2 233-238
    PubMedGoogle Scholar
  • 24 Friedman J H, Lannon M C. Clozapine-responsive tremor in Parkinson's disease.  Mov Disord. 1990;  5 225-229
    CrossrefPubMedGoogle Scholar
  • 25 Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor.  Acta Neurol Scand. 1986;  73 295-297
    PubMedGoogle Scholar
  • 26 Happe S, Pirker W, Sauter C. et al . Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil.  J Neurol. 2001;  248 632-634
    PubMedGoogle Scholar
  • 27 Hogl B, Saletu M, Brandauer E. et al . Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.  Sleep. 2002;  25 905-909
    PubMedGoogle Scholar
  • 28 Aarsland D, Tandberg E, Larsen J P, Cummings J L. Frequency of dementia in Parkinson disease.  Arch Neurol. 1996;  53 538-542
    PubMedGoogle Scholar
  • 29 Emre M, Aarsland D, Albanese A. et al . Rivastigmine for dementia associated with Parkinson's disease.  N Engl J Med. 2004;  351 2509-2518
    CrossrefPubMedGoogle Scholar
  • 30 Berry R A, Murphy J F. Well-being of caregivers of spouses with Parkinson's disease.  Clin Nurs Res. 1995;  4 373-386
    PubMedGoogle Scholar
  • 31 Montgomery jr E B, Lieberman A, Singh G, Fries J F. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board.  Am J Med. 1994;  97 429-435
    CrossrefPubMedGoogle Scholar
  • 32 Noyes K, Dick A W, Holloway R G. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.  Med Decis Making. 2004;  24 472-485
    CrossrefPubMedGoogle Scholar
  • 33 Hempel A G, Wagner M L, Maaty M A, Sage J I. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.  Ann Pharmacother. 1998;  32 878-883
    PubMedGoogle Scholar
  • 34 Przuntek H, Welzel D, Gerlach M. et al . Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.  J Neural Transm Gen Sect. 1996;  103 699-715
    CrossrefPubMedGoogle Scholar
  • 35 Rascol O, Brooks D J, Korczyn A D. et al . A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.  N Engl J Med. 2000;  342 1484-1491
    CrossrefPubMedGoogle Scholar
  • 36 Whone A L, Watts R L, Stoessl A J. et al . Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.  Ann Neurol. 2003;  54 93-101
    CrossrefPubMedGoogle Scholar
  • 37 Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.  Arch Neurol. 2004;  61 657-660
    CrossrefPubMedGoogle Scholar
  • 38 Fahn S, Oakes D, Shoulson I. et al . Levodopa and the progression of Parkinson's disease.  N Engl J Med. 2004;  351 2498-2508
    CrossrefPubMedGoogle Scholar
  • 39 Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.  Mov Disord. 1996;  11 327-329
    CrossrefPubMedGoogle Scholar
  • 40 Müngersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease.  J Neural Transm. 2001;  108 1309-1317
    CrossrefPubMedGoogle Scholar
  • 41 Müller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease.  Clin Neuropharmacol. 2003;  26 109-111
    PubMedGoogle Scholar
  • 42 Meissner W, Trottenberg T, Klaffke S. et al . Apomorphine therapy versus deep rain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease.  Nervenarzt. 2001;  72 924-927
    CrossrefPubMedGoogle Scholar
  • 43 Spottke E A, Volkmann J, Lorenz D. et al . Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.  J Neurol. 2002;  249 759-766
    PubMedGoogle Scholar
  • 44 Drucker-Colin R, Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status.  Cell Mol Neurobiol. 2004;  24 301-316
    CrossrefPubMedGoogle Scholar
  • 45 Harrower T P, Barker R A. Is there a future for neural transplantation?.  BioDrugs. 2004;  18 141-153
    PubMedGoogle Scholar
  • 46 Olanow C W, Goetz C G, Kordower J H. et al . A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.  Ann Neurol. 2003;  54 403-414
    CrossrefPubMedGoogle Scholar
  • 47 Berney A, Vingerhoets F, Perrin A. et al . Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients.  Neurology. 2002;  59 1427-1429
    CrossrefPubMedGoogle Scholar
  • 48 Lyons K E, Pahwa R. Deep brain stimulation in Parkinson's disease.  Curr Neurol Neurosci Rep. 2004;  4 290-295
    PubMedGoogle Scholar
  • 49 Charles P D, Padaliya B B, Newman W J. et al . Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.  Parkinsonism Relat Disord. 2004;  10 475-479
    CrossrefPubMedGoogle Scholar
  • 50 D'Ausilio A, Marconi S, Antonini A. et al . Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase.  Recenti Prog Med. 2003;  94 484-493
    PubMedGoogle Scholar
  • 51 Meissner W, Schreiter D, Volkmann J. et al . Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany.  J Neurol. 2005;  252 218-223
    CrossrefPubMedGoogle Scholar
  • 52 Bryson H M, Milne R J, Chrisp P. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.  Pharmacoeconomics. 1992;  2 118-136
    PubMedGoogle Scholar
  • 53 Diener H C. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York; Georg Thieme Verlag 2003
    Google Scholar
  • 54 Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects.  J Neural Transm. 2004;  111 201-216
    CrossrefPubMedGoogle Scholar

Prof. Dr. Thomas Müller

Neurologische Universitätsklinik im St.-Josef-Hospital · Ruhr-Universität Bochum

Gudrunstraße 56

44791 Bochum

Email: thomas.mueller@ruhr-uni-bochum.de

      >